Loading
Vinorelbine is a vinca chemotherapy for lung and breast cancer, available orally, and is now part of maintenance therapy that improved survival in childhood rhabdomyosarcoma.
Vinorelbine is a semi-synthetic vinca alkaloid that binds tubulin and blocks mitosis, with relative selectivity for mitotic over axonal microtubules and therefore less neuropathy than older vincas. It was approved in the EU in 1989 and in the US in 1994 for advanced NSCLC as a single agent or with cisplatin, and cisplatin-vinorelbine was the adjuvant regimen in the ANITA and JBR.10 trials that established post-operative chemotherapy in lung cancer. It is also used in metastatic breast cancer, mesothelioma and Hodgkin lymphoma salvage, and its oral formulation allows metronomic low-dose schedules. In children with high-risk rhabdomyosarcoma, maintenance vinorelbine with cyclophosphamide improved overall survival in the EpSSG RMS 2005 trial. Neutropenia is the main toxicity. Vinorelbine is an old chemotherapy that keeps finding new roles.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Tubulin-binding antimitotic with relative selectivity for mitotic over axonal microtubules (less neuropathy).
1.Vinorelbine slips into a pocket on its target.
Given by infusion or injection in a clinic or hospital outpatient department, so it is a Part B drug: Medicare pays 80% after the Part B deductible and the patient owes 20% coinsurance, uncapped in Original Medicare unless a Medigap policy applies. Generic.
Multi-source generic; covered under the medical benefit without prior authorisation in most plans, as part of standard regimens.
Sources: Medicare.gov: Chemotherapy · Medicare.gov: Prescription drugs (outpatient, Part B). Not medical or financial advice; verify with your plan.
Sources: NICE search: vinorelbine. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| US | 1994 | Advanced NSCLC as single agent or with cisplatin |
| EU | 1989 | NSCLC, metastatic breast cancer |
Read for the class this product belongs to (vinca alkaloids) unless the answer names the product. Population figures from the cohorts named, not a prediction for one person. Blank where no source gives a recovery figure.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Vinorelbine" OR ABSTRACT:"Vinorelbine" OR TITLE:"Navelbine" OR ABSTRACT:"Navelbine") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Vinorelbine, not a curated reading list.
Shares A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Cancer(PANKU-Breast01), Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer, A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer, Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer and the tag generic.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag generic.
Shares Lung cancer (all types), Non-small-cell lung cancer and the tag generic.
Shares HR-positive / HER2-negative breast cancer, Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.
Shares Cytotoxic chemotherapy and the tag generic.